📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
3 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
NEUTRAL
TOTAL VIEWS
32
ALKS Latest News & AI Sentiment Analysis
3 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 7 ARTICLES
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?
Alkermes (ALKS) delivered a mixed earnings print that highlights the tension between operational momentum and valuation reset dynamics....
Could Alkermes plc (ALKS) Stock Rebound After Investors Look Beyond Near-Term Profit Pressure?
Alkermes (ALKS) experienced a 5% single-day decline following its Q2 2026 earnings release, reflecting near-term market disappointment...
Tarsus Pharmaceuticals to buy Alkeus Pharmaceuticals
Tarsus Pharmaceuticals has announced an acquisition of Alkeus Pharmaceuticals, a consolidation move within the biopharmaceutical sector....
Alkermes expects Q3 2026 total revenues of $450M-$470M as CEO transition and orexin readouts approach (NASDAQ:ALKS)
Alkermes (ALKS) provided Q3 2026 revenue guidance of $450M–$470M during its Q2 earnings call, framing a period marked by operational...
Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript
Alkermes plc (ALKS) released Q2 2026 earnings results via earnings call on July 28, 2026. The company's earnings call transcript...
Granules India gets key US advantage for Generic Lumryz Tablets
Granules India has secured First-to-File (FTF) status for a generic version of Lumryz tablets in the United States market. This...
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS)
Alkermes (ALKS) is being positioned as a buy on two fundamental catalysts: the Avadel acquisition and positive clinical data for its...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice